Core Viewpoint - Fuhong Hanlin (02696) experienced a significant stock price increase following news of a hedge fund's stake increase and FDA approval for its biosimilar products [1] Group 1: Stock Performance - Fuhong Hanlin's stock rose over 6% in early trading, with a current increase of 5.09%, reaching HKD 79.45, with a trading volume of HKD 32.33 million [1] Group 2: Institutional Investment - Point72, a hedge fund managed by Steve Cohen, increased its holdings in Fuhong Hanlin by 243,800 shares at an average price of HKD 83.5703 per share, totaling approximately HKD 20.37 million [1] - Following this purchase, Point72's total shareholding in Fuhong Hanlin rose to 8.24 million shares, increasing its ownership percentage from 4.89% to 5.04% [1] Group 3: FDA Approval - Fuhong Hanlin announced that the U.S. FDA has approved the market applications for two biosimilar products: BILDYOS (denosumab-nxxp) and BILPREVDA (denosumab-nxxp) [1] - These products are biosimilars to PROLIA (denosumab) and XGEVA (denosumab) [1] - In 2022, Fuhong Hanlin entered into a licensing and supply agreement with Organon, granting Organon exclusive commercialization rights for several biosimilars, including BILDYOS and BILPREVDA, outside of China [1]
复宏汉霖早盘涨超6% 股东Point72近期增持股份 公司旗下两款产品获FDA批准上市